FDA-approved drug may reverse T-cell exclusion in fibrolamellar liver cancer
Immunotherapy—which activates the body's own immune system to kill cancer cells—has not worked well against a rare and fatal liver cancer, but a new study finds an existing FDA-approved drug may allow the immunotherapy ...
Feb 17, 2026
0
0









